Prof. Weidong Wang 王卫东
Chief Physician, Professor
Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Combined chemoradiotherapy, molecular targeted therapy, cellular immunotherapy, and gene therapy for solid tumors including lung, esophageal, nasopharyngeal, brain, breast, liver, and cervical cancers. Palliative and supportive care for advanced tumors. Comprehensive treatment for elderly cancer patients.
Dr. Wang is a Chief Physician, Professor, and Director of the Fifth Radiotherapy Ward. A postdoctoral fellow in the United States and master’s supervisor, Dr. Wang has led multiple research projects funded by the National Natural Science Foundation and provincial authorities. Dr. Wang has published over 50 papers, including 15 SCI articles, and serves as a reviewer for several international journals.
Professional roles
- Standing Committee Member, Radiotherapy Professional Committee, Chinese Society of Geriatric Oncology
- Deputy Leader, Radiobiology Group, Radiation Oncology Branch, Chinese Medical Association
- Youth Committee Member, Radiotherapy Professional Committee, China Anti-Cancer Association
- Member, American Society for Radiation Oncology (ASTRO)
Name order: in Chinese the family name comes first (Wang Weidong). Papers usually list the name as Weidong Wang or Wang W.
Selected publications
43 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications. PubMed 41727427
- J Transl Med, 2025 (senior author): Recent progress in immune evasion mechanisms of triple-negative breast cancer. PubMed 41254706
- Front Immunol, 2025 (senior author): Short-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: a phase II randomized trial protocol (Tori-013). PubMed 40901464
- J Exp Clin Cancer Res, 2025 (senior author): Light-activatable manganese carbonate nanocubes elicit robust immunotherapy by amplifying endoplasmic reticulum stress-meditated pyroptotic cell death. PubMed 40380194
- J Transl Med, 2025 (senior author): Advances in tumor subclone formation and mechanisms of growth and invasion. PubMed 40259385
- BMC Cancer, 2025 (senior author): Infiltration and subtype analysis of CD3 + CD20 + T cells in lung cancer. PubMed 39885465
- Front Oncol, 2024 (senior author): Exploiting tertiary lymphoid structures gene signature to evaluate tumor microenvironment infiltration and immunotherapy response in colorectal cancer. PubMed 38846981
- J Magn Reson Imaging, 2024 (senior author): Analysis of the Correlation and Prognostic Significance of Tertiary Lymphoid Structures in Breast Cancer: A Radiomics-Clinical Integration Approach. PubMed 37526043
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion